Arne A Ittner

List of Publications by Year
in descending order

36 papers	1,984 citations	361388 20 h-index	377849 34 g-index
36 all docs	36 docs citations	36 times ranked	3343 citing authors

#	Article	IF	Citations
1	High Level Forebrain Expression of Active Tau Kinase p38Î³ Exacerbates Cognitive Dysfunction in Aged APP-transgenic Alzheimerâ€™s Mice. Neuroscience, 2022, 484, 53-65.	2.3	1
2	The behavioural phenotype of 14-month-old female TAU58/2 transgenic mice. Behavioural Brain Research, 2021, 397, 112943.	2.2	5
3	Interaction between the guanylate kinase domain of PSD-95 and the proline-rich region and microtubule binding repeats 2 and 3 of tau. Biochemistry and Cell Biology, 2021, 99, 1-11.	2.0	7
4	Reduction of advanced tau-mediated memory deficits by the MAP kinase p38Î³. Acta Neuropathologica, 2020, 140, 279-294.	7.7	24
5	Contribution of endogenous antibodies to learning deficits and astrocytosis in human P301S mutant tau transgenic mice. Scientific Reports, 2020, 10, 13845.	3.3	2
6	Functions of p38 MAP Kinases in the Central Nervous System. Frontiers in Molecular Neuroscience, 2020, 13, 570586.	2.9	80
7	Onset of hippocampal network aberration and memory deficits in P301S tau mice are associated with an early gene signature. Brain, 2020, 143, 1889-1904.	7.6	12
8	Chronic cannabidiol (CBD) treatment did not exhibit beneficial effects in 4-month-old male TAU58/2 transgenic mice. Pharmacology Biochemistry and Behavior, 2020, 196, 172970.	2.9	13
9	Novel Behavioural Characteristics of Male Human P301S Mutant Tau Transgenic Mice â€“ A Model for Tauopathy. Neuroscience, 2020, 431, 166-175.	2.3	11
10	Mapping p38Î± mitogenâ€activated protein kinase signaling by proximityâ€dependent labeling. Protein Science, 2020, 29, 1196-1210.	7.6	22
11	CNS cell typeâ€“specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. Journal of Biological Chemistry, 2019, 294, 14149-14162.	3.4	10
12	Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2019, 39, 9645-9659.	3.6	22
13	Generation of a New Tau Knockout (tauÎ”ex1) Line Using CRISPR/Cas9 Genome Editing in Mice. Journal of Alzheimer's Disease, 2018, 62, 571-578.	2.6	29
14	An N-terminal motif unique to primate tau enables differential proteinâ€“protein interactions. Journal of Biological Chemistry, 2018, 293, 3710-3719.	3.4	53
15	Neuronal MAP kinase p38Î± inhibits c-Jun N-terminal kinase to modulate anxiety-related behaviour. Scientific Reports, 2018, 8, 14296.	3.3	27
16	Dendritic Tau in Alzheimerâ€™s Disease. Neuron, 2018, 99, 13-27.	8.1	178
17	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. Neuroscience and Biobehavioral Reviews, 2017, 74, 126-138.	6.1	23
18	Ring-opened aminothienopyridazines as novel tau aggregation inhibitors. MedChemComm, 2017, 8, 1275-1282.	3.4	7

#	Article	IF	Citations
19	[P4â€“093]: SITEâ€SPECIFIC PHOSPHORYLATION OF TAU INHIBITS AMYLOIDâ€Î²2 TOXICITY IN ALZHEIMER's MICE. Alzheimer's and Dementia, 2017, 13, P1294.	0.8	0
20	Tau exacerbates excitotoxic brain damage in an animal model of stroke. Nature Communications, 2017, 8, 473.	12.8	134
21	Neuronal network disintegration: common pathways linking neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1234-1241.	1.9	106
22	Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia. Neuroscience Letters, 2016, 631, 24-29.	2.1	34
23	Site-specific phosphorylation of tau inhibits amyloid-Î2 toxicity in Alzheimerâ€™s mice. Science, 2016, 354, 904-908.	12.6	241
24	No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapttm1(EGFP)Kit GFP Knockin Mice. PLoS ONE, 2016, 11, e0163236.	2.5	35
25	Tauâ€targeting passive immunization modulates aspects of pathology in tau transgenic mice. Journal of Neurochemistry, 2015, 132, 135-145.	3.9	70
26	p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2014, 2, 149.	5.2	65
27	The nucleotide exchange factor SIL1 is required for glucose-stimulated insulin secretion from mouse pancreatic beta cells in vivo. Diabetologia, 2014, 57, 1410-1419.	6.3	22
28	Regulation of PTEN activity by p38Î´-PKD1 signaling in neutrophils confers inflammatory responses in the lung. Journal of Experimental Medicine, 2012, 209, 2229-2246.	8.5	80
29	Hairless promotes PPARÎ3 expression and is required for white adipogenesis. EMBO Reports, 2012, 13, 1012-1020.	4.5	6
30	Lessons from Tau-Deficient Mice. International Journal of Alzheimer's Disease, 2012, 2012, 1-8.	2.0	99
31	Tauâ€targeted treatment strategies in Alzheimer's disease. British Journal of Pharmacology, 2012, 165, 1246-1259.	5.4	114
32	Regulation of PTEN activity by p38d-PKD1 signaling in neutrophils confers inflammatory responses in the lung. Journal of Cell Biology, 2012, 199, i6-i6.	5.2	0
33	Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice. PLoS ONE, 2011, 6, e26860.	2.5	142
34	Reduced secretagogin expression in the hippocampus of P301L tau transgenic mice. Journal of Neural Transmission, 2011, 118, 737-745.	2.8	19
35	Brief update on different roles of tau in neurodegeneration. IUBMB Life, 2011, 63, 495-502.	3.4	42
36	MAPK signalling in cellular metabolism: stress or wellness?. EMBO Reports, 2010, 11, 834-840.	4.5	249